BACKGROUND & AIMS:Enteral glutamine may have protective effects on gut function and reduce metabolic stress in patients receiving radiochemotherapy. The aim of our study was to evaluate its influence in patients with rectal cancer undergoingpreoperative radiochemotherapy. METHODS: We performed a randomized double blind, placebo controlled pilot study in 33 patients. 30 g of glutamine, average dose 0.41 g/kg (SD = 0.07) g/kg/day was administered orally in three doses per day for five weeks during preoperative radiochemotherapy of rectal cancer. 30 g of maltodextrin was given as placebo. Body weight was measured and NRS 2002 screening was performed before and after treatment. Bowel function was evaluated by stool consistency and frequency. Plasma levels of inflammatory parameters and hormones were measured. RESULTS: There was no difference between groups in frequency and severity of diarrhoea during radiochemotherapy (p = 0.5 and p = 0.39 respectively), insulin levels significantly increased in both groups, IL-6 only in glutamine group. CONCLUSION: Results of this small pilot study in rectal cancer patients receivingpreoperative radiochemotherapy, showed that ingestion of larger quantities of glutamine given more often as previously reported did not diminish the incidence and severity of diarrhoea and did not affect inflammatory and metabolic activity compared to the placebo treatment with maltodextrin.
RCT Entities:
BACKGROUND & AIMS: Enteral glutamine may have protective effects on gut function and reduce metabolic stress in patients receiving radiochemotherapy. The aim of our study was to evaluate its influence in patients with rectal cancer undergoing preoperative radiochemotherapy. METHODS: We performed a randomized double blind, placebo controlled pilot study in 33 patients. 30 g of glutamine, average dose 0.41 g/kg (SD = 0.07) g/kg/day was administered orally in three doses per day for five weeks during preoperative radiochemotherapy of rectal cancer. 30 g of maltodextrin was given as placebo. Body weight was measured and NRS 2002 screening was performed before and after treatment. Bowel function was evaluated by stool consistency and frequency. Plasma levels of inflammatory parameters and hormones were measured. RESULTS: There was no difference between groups in frequency and severity of diarrhoea during radiochemotherapy (p = 0.5 and p = 0.39 respectively), insulin levels significantly increased in both groups, IL-6 only in glutamine group. CONCLUSION: Results of this small pilot study in rectal cancerpatients receiving preoperative radiochemotherapy, showed that ingestion of larger quantities of glutamine given more often as previously reported did not diminish the incidence and severity of diarrhoea and did not affect inflammatory and metabolic activity compared to the placebo treatment with maltodextrin.
Authors: Joanne M Bowen; Rachel J Gibson; Janet K Coller; Nicole Blijlevens; Paolo Bossi; Noor Al-Dasooqi; Emma H Bateman; Karen Chiang; Charlotte de Mooij; Bronwen Mayo; Andrea M Stringer; Wim Tissing; Hannah R Wardill; Ysabella Z A van Sebille; Vinisha Ranna; Anusha Vaddi; Dorothy Mk Keefe; Rajesh V Lalla; Karis Kin Fong Cheng; Sharon Elad Journal: Support Care Cancer Date: 2019-07-08 Impact factor: 3.603
Authors: Theresa A Lawrie; John T Green; Mark Beresford; Linda Wedlake; Sorrel Burden; Susan E Davidson; Simon Lal; Caroline C Henson; H Jervoise N Andreyev Journal: Cochrane Database Syst Rev Date: 2018-01-23
Authors: M Schmidt-Hieber; J Bierwirth; D Buchheidt; O A Cornely; M Hentrich; G Maschmeyer; E Schalk; J J Vehreschild; Maria J G T Vehreschild Journal: Ann Hematol Date: 2017-11-24 Impact factor: 3.673
Authors: Bae Kwon Jeong; Jin Ho Song; Hojin Jeong; Hoon Sik Choi; Jung Hwa Jung; Jong Ryeal Hahm; Seung Hoon Woo; Myeong Hee Jung; Bong-Hoi Choi; Jin Hyun Kim; Ki Mun Kang Journal: Oncotarget Date: 2016-03-22